Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month High – Still a Buy?

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) reached a new 52-week high during trading on Monday . The stock traded as high as $10.57 and last traded at $10.0480, with a volume of 2562640 shares changing hands. The stock had previously closed at $9.56.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Wednesday. Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. The Goldman Sachs Group upped their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Needham & Company LLC raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Thursday, September 18th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.57.

Amicus Therapeutics Price Performance

The stock has a market cap of $2.97 billion, a PE ratio of -80.27 and a beta of 0.66. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The firm’s 50 day moving average price is $8.61 and its two-hundred day moving average price is $7.26.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. The business had revenue of $169.06 million for the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a negative net margin of 6.67% and a negative return on equity of 5.07%. The business’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 EPS. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts expect that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, insider David Michael Clark sold 25,643 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $9.51, for a total value of $243,864.93. Following the transaction, the insider directly owned 322,618 shares of the company’s stock, valued at $3,068,097.18. The trade was a 7.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amicus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. CIBC Bancorp USA Inc. purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $234,000. Sender Co & Partners Inc. purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $272,000. PharVision Advisers LLC bought a new stake in Amicus Therapeutics during the 3rd quarter worth approximately $95,000. XTX Topco Ltd purchased a new position in shares of Amicus Therapeutics in the third quarter valued at about $516,000. Finally, Parkman Healthcare Partners LLC lifted its holdings in shares of Amicus Therapeutics by 177.2% in the third quarter. Parkman Healthcare Partners LLC now owns 1,687,318 shares of the biopharmaceutical company’s stock worth $13,296,000 after buying an additional 1,078,681 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.